Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).

Neoh, Chin Fen; Liew, Danny; Slavin, Monica A; Marriott, Debbie; Chen, Sharon C-A; Morrissey, Orla; Stewart, Kay; Kong, David C M

Neoh, Chin Fen; Liew, Danny; Slavin, Monica A; Marriott, Debbie; Chen, Sharon C-A; Morrissey, Orla; Stewart, Kay; Kong, David C M.

Affiliation

Neoh CF; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University Parkville campus, Parkville, Australia.

Mycoses ; 56(5): 532-42, 2013 Sep.

Article in En | MEDLINE | ID: mdl-23496163

Subject(s)

Amphotericin B/therapeutic use; Antifungal Agents/therapeutic use; Candidemia/drug therapy; Candidiasis, Invasive/drug therapy; Echinocandins/therapeutic use; Lipopeptides/therapeutic use; Amphotericin B/economics; Antifungal Agents/economics; Australia; Echinocandins/economics; Health Care Costs; Humans; Lipopeptides/economics; Micafungin; Treatment Outcome

Key words

Candida spp.; Micafungin; cost; economic; liposomal amphotericin B; modelling

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amphotericin B / Echinocandins / Lipopeptides / Candidemia / Candidiasis, Invasive / Antifungal Agents Type of study: Health_economic_evaluation / Prognostic_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Mycoses Journal subject: MICROBIOLOGIA Year: 2013 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google